The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Trials to watch in the mantle cell lymphoma space
Krish Patel, MD, Sarah Cannon Cancer Institute, Nashville, TN, outlines two exciting trials to watch in the field of mantle cell lymphoma (MCL): the GLOBRYTE trial (NCT06084936) and the BRUIN MCL-321 study (NCT04662255). Dr Patel highlights the potential for these trials to be practice-changing, providing valuable insights into the optimal treatment strategies for patients with this malignancy. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So a lot of exciting things happening in the relapsed/refractory setting in mantle cell lymphoma. In terms of what I would say are going to be potentially practice-changing trials. Two that I would highlight, we have the GLOBRYTE trial. GLOBRYTE is a Phase III study that’s being done globally that randomizes patients to glofitamab, a CD3/ CD20 bispecific antibody in relapsed/refractory mantle cell, or to investigators’ choice of either chemotherapy or lenalidomide and rituximab...
So a lot of exciting things happening in the relapsed/refractory setting in mantle cell lymphoma. In terms of what I would say are going to be potentially practice-changing trials. Two that I would highlight, we have the GLOBRYTE trial. GLOBRYTE is a Phase III study that’s being done globally that randomizes patients to glofitamab, a CD3/ CD20 bispecific antibody in relapsed/refractory mantle cell, or to investigators’ choice of either chemotherapy or lenalidomide and rituximab. So that study I think is going to really help define for us where should we be using bispecific antibodies in mantle cell lymphoma. Another trial that I’ll highlight is the BRUIN MCL-321 study. That’s a Phase III study of a non-covalent BTK inhibitor, pirtobrutinib. Pirtobrutinib is currently approved in patients who have had a covalent BTK inhibitor, but the 321 study is a head-to-head comparison of pirtobrutinib to investigators’ choice of covalent BTK inhibitors so ibrutinib, acalabrutinib, or zanabrutinib in patients with relapsed/refractory mantle cell and that will also help us to further define where should we be positioning pirtobrutinib. So these are studies that we’re going to really pay attention to and want to see those readouts from when they’re ready.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Sunesis Pharmaceuticals: Consultancy, Research Funding; CRISPR Therapeutics: Research Funding; Fate Therapeutics: Research Funding; Genentech/Roche: Consultancy, Research Funding; MEI Pharma: Consultancy, Research Funding; Merck: Consultancy, Research Funding; Morphosys: Consultancy; AbbVie: Consultancy; Adaptive Biotechnologies: Research Funding; Nurix: Research Funding; Trillium Therapeutics/Pfizer: Consultancy, Research Funding; Pharmacyclics/Janssen: Consultancy, Research Funding; TG Therapeutics: Consultancy, Speakers Bureau; Kite: Consultancy, Research Funding, Speakers Bureau; Loxo Oncology: Consultancy, Research Funding; Epizyme: Consultancy, Research Funding; Curis, Inc: Research Funding; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; ADC Therapeutics: Consultancy; Xencor: Consultancy, Research Funding; BeiGene: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Caribou Biosciences: Consultancy.
